COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

30,252 Articles (22,236 medRxiv, 8,016 bioRxiv)

Most recent first Previous |  Page 1084: Articles 10831-10840  | Next

Social and mental health risks faced by undocumented migrants during the COVID-19 pandemic: Evidence from three surveys in France
Gosselin, A., Longchamps, C., Oulahal, R., Derluyn, I., Ducarroz, S., Skovdal, M., Verelst, A., Sturm, G., Desgrees du Lou, A., Melchior, M.
10.1101/2021.10.14.21264999 — Posted: 2021-10-14
Variable inhibition of unwinding rates of DNA catalyzed by the SARS-Cov-2 (COV19) helicase nsp13 by structurally distinct single DNA lesions.
Sales, A. H., Ciervo, S., Lupoli, T., Shafirovich, V., Geacintov, N. E.
10.1101/2021.10.13.464299 — Posted: 2021-10-14
Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021
Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., Wallace, A. W.
10.1101/2021.10.13.21264966 — Posted: 2021-10-14 Discussion: Onsite
Modelling airborne transmission of SARS-CoV-2 using CARA: Risk assessment for enclosed spaces
Henriques, A., Mounet, N., Aleixo, L., Elson, P., Devine, J., Azzopardi, G., Andreini, M., Rognlien, M., Tarocco, N., Tang, J.
10.1101/2021.10.14.21264988 — Posted: 2021-10-14
Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution
Nunes, D. R., Braconi, C. T., Ludwig-Begall, L., Arns, C. W., Janini, L. M. R., Duraes-Carvalho, R.
10.1101/2021.10.14.21264474 — Posted: 2021-10-14
Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test?
Hofmann, N. E., Grossegesse, M., Neumann, M., Schaade, L., Nitsche, A.
10.1101/2021.10.12.21264881 — Posted: 2021-10-14
Why one size fits all is not enough when designing immunity certificates for domestic use: a UK wide cross-sectional online survey
Niculaescu, C.-E., Sassoon, I., Avila, I. C.-L., Colak, O., Jun, G. T., Balatsoukas, P.
10.1101/2021.10.12.21264898 — Posted: 2021-10-14
Public acceptability of non-pharmaceutical interventions to control a pandemic in the United Kingdom: a discrete choice experiment
Loria-Rebolledo, L. E., Ryan, M., Watson, V., Genie, M. G., Sakowsky, R. A., Powell, D., Paranjothy, S.
10.1101/2021.10.12.21264883 — Posted: 2021-10-14
Increased mTOR signaling, impaired autophagic flux and cell-to-cell viral transmission are hallmarks of SARS-CoV-2 infection.
Celeste Maktura, G., Luscher Dias, T., Pereira Zambalde, E., Brenha, B., R. Amorim, M., Nunes Santos, L., Buscaratti, L., Gabriel de Angeli Elston, J., Mara, C., Camargo Silva Mancini, M., Carolina Betim Pavan, I., A. Toledo-Teixeira, D., Bispo-dos-Santos, K., L. Parise, P., Primon Muraro, S., Fabiano de Souza, G., Paula Morelli, A., Guilherme Salvino da Silva, L., Maia Santos de Castro, I., Oliveira Barbosa, G., G. Ludwig, R., L. Knittel, T., D. Saccon, T., A. Mori, M., Granja, F., F. Carvalho, H., Lamberti Pinto da Silva, L., I. Nakaya, H., Luiz Proenca-Modena, J., Moreira Simabuco, F., Marques-Souza, H.
10.1101/2021.10.13.464225 — Posted: 2021-10-14
The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants
Cao, L., Li, Y., Yang, S., Li, G., Zhou, Q., Sun, J., Xu, T., Yang, Y., Zhu, T., Huang, S., Ji, Y., Cong, F., Luo, Y., Zhu, Y., Luan, H., Zhang, H., Chen, J., Liu, X., Wang, P., Yu, Y., Xing, F., Ke, B., Zheng, H., Deng, X., Zhang, W., Li, C., Zhang, Y., Zhao, J., Zhang, X., Guo, D.
10.1101/2021.10.13.463130 — Posted: 2021-10-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).